Please wait while the formulary information is being retrieved.
PALONOSETRON HCL (palonosetron HCl)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- Palonosetron Intravenous Syringe
- Palonosetron Intravenous Solution
- Aloxi Intravenous Solution
- By Indication
0.25 mg/5 mL intravenous syringe
- Inject 5 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
palonosetron 0.25 mg/5 mL intravenous syringe
- Inject 5 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
palonosetron 0.25 mg/2 mL intravenous solution
- Inject 2 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
palonosetron 0.25 mg/5 mL intravenous solution
- Inject 5 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
0.25 mg/5 mL intravenous solution
- Inject 5 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
Prevention of chemotherapy-induced nausea and vomiting
- Inject 5 milliliters (0.25 mg) over 30 second(s) by intravenous routeonce 30 minutes before chemotherapy
Prevention of post-operative nausea and vomiting
- Inject 1.5 milliliters (0.075 mg) over 10 second(s) by intravenous route immediately before induction of anesthesia
- None
Contraindicated
- None
Severe
Moderate
- Conzip
- Synapryn
- tramadol
- tramadol-acetaminophen
- tramadol-glucosamine
- Ultracet
- Ultram
- Ultram Er
- None
Contraindicated
- Neuroleptic malignant syndrome
- Serotonin syndrome
Severe
Moderate
- None
PALONOSETRON HCL (palonosetron HCl)
- Prevention of chemotherapy-induced nausea and vomiting
- Prevention of post-operative nausea and vomiting
- None
- Constipation
- Headache disorder
More Frequent
Severe
Less Severe
- Bradycardia
- Hyperkalemia
- Hypoventilation
- Chills
- Diarrhea
- Dizziness
- General weakness
- Pruritus of skin
- Symptoms of anxiety
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Dyskinesia
- Extrasystoles
- Gastrointestinal hypomotility
- Hyperglycemia
- Hypersensitivity drug reaction
- Hypertension
- Hypokalemia
- Hypotension
- Laryngismus
- Metabolic acidosis
- Myocardial ischemia
- Serotonin syndrome
- Sinus node dysfunction
- Sinus tachycardia
- Supraventricular premature beats
- Tachycardia
Less Severe
- Abnormal hepatic function tests
- Acute abdominal pain
- Allergic dermatitis
- Amblyopia
- Anorexia
- Arthralgias
- Drowsy
- Dyspepsia
- Euphoria
- Fatigue
- Fever
- Flatulence
- Flu-like symptoms
- Flushing
- Glycosuria
- Hiccups
- Hypersomnia
- Injection site sequelae
- Insomnia
- Motion sickness
- Ocular irritation
- Paresthesia
- Skin rash
- Tinnitus
- Urinary retention
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Palonosetron (Inj)
Safety and efficacy not established in infants age < 1 month.
- 1 Day – 29 Days
- Safety and efficacy not established in infants age < 1 month.
Palonosetron
- Severity Level:
2
- Additional Notes: Insuff human data; animal data do not sugg dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Palonosetron
May be excreted; short term use may not adversely affect infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | May be excreted; short term use may not adversely affect infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool